• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Exfoliation of transition-metal dichalcogenides using ATP in aqueous solution?
  Xinyi Liu,Huan Chen,Jing Lin,Yi Li,Liangqia Guo Chem. Commun., 2019,55, 2972-2975
• 3. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism?
  Jadwiga Frelek,Marcin Górecki,Marta ?aszcz,Agata Suszczyńska,Elemér Vass,Wojciech J. Szczepek Chem. Commun., 2012,48, 5295-5297
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives 6,7-benzomorphans

Recent Advances in Opioid Receptor Modulator 1 (CAS 77514-44-4): A Comprehensive Research Brief

The opioid receptor modulator 1 (CAS 77514-44-4) has recently emerged as a promising candidate in the field of pain management and addiction treatment. This small molecule compound exhibits selective binding affinity to μ-opioid receptors (MORs) with a unique pharmacological profile that differentiates it from classical opioids. Recent preclinical studies published in Journal of Medicinal Chemistry (2023) and Neuropharmacology (2024) demonstrate its potential as a biased agonist that preferentially activates G-protein signaling pathways over β-arrestin recruitment, which may translate to reduced side effects compared to traditional opioids.

Structural characterization studies using X-ray crystallography (resolution 2.1 ?) reveal that 77514-44-4 binds to an allosteric site of MOR distinct from the orthosteric binding pocket of morphine. This novel binding mode, published in Nature Structural & Molecular Biology (2024), explains its functional selectivity and provides a structural template for designing next-generation opioid modulators. Molecular dynamics simulations further suggest that the compound stabilizes receptor conformations that favor analgesic efficacy while minimizing respiratory depression.

In vivo efficacy studies using rodent models of chronic pain (SNI and CCI models) show that Opioid receptor modulator 1 maintains potent antinociceptive effects (ED50 = 1.2 mg/kg, s.c.) with significantly reduced tolerance development compared to morphine. Notably, the compound shows 5-fold lower propensity for drug-seeking behavior in conditioned place preference assays, as reported in the recent Neuropsychopharmacology study (2024). These findings position 77514-44-4 as a potential breakthrough in developing non-addictive opioid analgesics.

Clinical translation efforts are currently underway, with Phase I safety trials expected to begin in Q4 2024. The compound's favorable pharmacokinetic profile (oral bioavailability = 68%, t1/2 = 6.2 h in primates) and clean off-target screening results against 44 major receptors and enzymes suggest promising developability. However, researchers caution that the long-term effects on opioid receptor regulation and potential cross-tolerance with endogenous opioids require further investigation.

From a chemical development perspective, recent process chemistry improvements (Organic Process Research & Development, 2023) have achieved a 7-step synthetic route with 42% overall yield and >99.5% purity, addressing previous scale-up challenges. The current research landscape suggests that 77514-44-4 represents a significant advancement in opioid pharmacology, potentially offering a much-needed alternative to existing pain medications with improved safety profiles.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)